To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

PHASE1TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Conditions
PainHealthy
Interventions
DRUG

BI 660848

2 mg oral drinking solution

DRUG

BI 660848

10 mg oral drinking solution

DRUG

BI 660848

20 mg oral drinking solution

DRUG

BI 660848

50 mg oral drinking solution

DRUG

BI 660848

100 mg oral drinking solution

DRUG

BI 660848

150 mg oral drinking solution

DRUG

BI 660848

200 mg oral drinking solution

DRUG

BI 660848

400 mg oral drinking solution

DRUG

BI 660848

600 mg oral drinking solution

DRUG

BI 660848

10,0 mg immediate release tablet

DRUG

BI 660848

50,0 mg immediate release tablet

DRUG

Placebo

matching placebo (oral drinking solution and IR tablets)

Trial Locations (1)

Unknown

1284.1.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY